Watson Pharmaceuticals Gets Bad FDA Report

Watson Pharmaceuticals Inc.’s manufacturing facility in Corona employs poorly trained lab technicians, according to a report by the Food and Drug Administration. The company said last month that it won’t be able to get new products approved until violations are fixed to the agency’s satisfaction. “There are instances where employees have not shown that they understand basic laboratory procedures,” wrote FDA inspectors in the report dated Oct. 22. Company officials weren’t available for comment. Watson’s shares fell $1.50 to close at $36.81 on the New York Stock Exchange.